KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial.

Shanu Modi, William Jacot, Hiroji Iwata, Yeon Hee Park, Maria Vidal Losada, Wei Li, Junji Tsurutani, Naoto T Ueno, Khalil Zaman, Aleix Prat, Konstantinos Papazisis, Hope S Rugo, Toshinari Yamashita, Nadia Harbeck, Seock-Ah Im, Michelino De Laurentiis, Jean-Yves Pierga, Xiaojia Wang, Andrea Gombos, Eriko Tokunaga, Cecilia Orbegoso Aguilar, Lotus Yung, Feng Xiao, Yingkai Cheng, David Cameron

Nat Med 31(12) 4205-4213

PMID41062831
PMCIDPMC12705423
DOI10.1038/s41591-025-03981-4
发表日期2025-10-08
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

In DESTINY-Breast04 ( NCT03734029 ), trastuzumab deruxtecan (T-DXd) significantly improved overall survival (OS) and progression-free survival compared with treatment of physician's choice of chemotherapy (TPC) for patients with human epidermal growth factor receptor 2-low (HER2-low) (immunohistochemistry (IHC) 1+ or IHC 2+/in situ hybridization-negative) metastatic breast cancer. After an extended median follow-up of 32.0 months, median OS in the overall cohort was 22.9 months for T-DXd and 16.8 months for TPC (hazard ratio 0.69; 95% confidence interval 0.55-0.86). For the hormone receptor-positive cohort, median OS was 23.9 and 17.6 months for T-DXd and TPC, respectively (hazard ratio 0.69; 95% confidence interval 0.55-0.87). Median OS also favored T-DXd in exploratory analyses of hormone receptor-negative, estrogen receptor IHC 1%-10% and estrogen receptor IHC >10% cohorts. The overall safety profile of T-DXd was acceptable and generally manageable. Results confirm T-DXd as standard of care after prior chemotherapy in patients with HER2-low metastatic breast cancer. ClinicalTrials.gov identifier: NCT03734029 .

KM 提取结果

1 个 Figure · 2 个 KM 面板

进入结果中心
KM Figure2 个面板

Extended Data Fig. 3

Kaplan-Meier analysis of PFS by investigator in (a) HR+ and (b) HR− cohorts. CI, confidence interval; HR, hormone receptor; PFS, progression-free survival; T-DXd, trastuzumab deruxtecan; TPC, treatment of physician’s choice of chemotherapy. For the OS and PFS by investigator endpoints for the HR+ and all patient cohorts, the HR status is based on data collected using the interactive web-response and voice-response system at the time of randomization, which includes patients who were misstratified.

A

PFS

Extended Data Fig. 3 · Panel A

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel A 是同一 Extended Data Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线缺失:预期 2 条,实际恢复 1 条曲线 2:off origin start曲线 2:extreme upward reversal
查看结果
B

PFS

Extended Data Fig. 3 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Extended Data Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似图例或人工水平线:轨迹出现不合理的共同平台疑似图例或人工水平线:轨迹出现不合理的共同平台曲线 2:extreme upward reversal
查看结果
其他 Figure(5,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Patient disposition and Kaplan–Meier analysis of OS in the overall cohort. Patient disposition ( a ) and OS in the overall cohort ( b ). Percentages depicted in the patient disposition figure are based on the number of patients in each arm. ‘Other’ in the patient disposition figure includes clinical progression, physician decision, lost to follow-up and other unknown reasons. For the OS and PFS by investigator endpoints for the HR+ and all patient cohorts, the HR status is based on data collected using the interactive web-response and voice-response system at the time of randomization, which includes patients who were misstratified. The dashed lines in the Kaplan-Meier curve depict the landmark OS rates at 24 and 36 months.
非 KM Figure
Fig. 2Kaplan–Meier analysis of OS in the HR+ and HR− cohorts. a , b , HR+ cohort ( a ) and HR− cohort ( b ). For the OS and PFS by investigator endpoints for the HR+ and all patient cohorts, the HR status is based on data collected using the interactive web-response and voice-response system at the time of randomization, which includes patients who were misstratified. The dashed lines depict the landmark OS rates at 24 and 36 months.
非 KM Figure
Fig. 3OS and PFS by investigator by best response to T-DXd. a , b , OS ( a ) and PFS ( b ). CR, complete response; PR, partial response; SD, stable disease.
非 KM Figure
Extended Data Fig. 1Subgroup analysis: OS in the (a) overall and (b) HR+ cohorts. CDK, cyclin-dependent kinase; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; HR, hormone receptor; IHC, immunohistochemistry; ISH, in situ hybridization; OS, overall survival; T-DXd, trastuzumab deruxtecan; TPC, treatment of physician’s choice of chemotherapy.
非 KM Figure
Extended Data Fig. 2Kaplan-Meier analysis of PFS by investigator in the overall cohort. CI, confidence interval; HR, hormone receptor; PFS, progression-free survival; T-DXd, trastuzumab deruxtecan; TPC, treatment of physician’s choice of chemotherapy. For the OS and PFS by investigator endpoints for the HR+ and all patient cohorts, the HR status is based on data collected using the interactive web-response and voice-response system at the time of randomization, which includes patients who were misstratified.
非 KM Figure